Vertex Pharmaceuticals Inc
VRTX XNASAbout Vertex Pharmaceuticals Inc
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Key Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $2.99B | $1.03B | $4.06 |
| FY 2025 | $12.00B | $3.95B | $15.46 |
| Q3 2025 | $3.08B | $1.08B | $4.24 |
| Q2 2025 | $2.96B | $1.03B | $4.02 |
TickerDaily Coverage
Get VRTX Alerts
Stay ahead with breaking news, price alerts, and expert analysis on Vertex Pharmaceuticals Inc.